Accuray and CIRC JV will cater to emerging radiation oncology systems market in China. Credit: Textefuermedizin.

US-based radiotherapy systems developer Accuray has formed a joint venture (JV) with China Isotope and Radiation Corporation (CIRC) to manufacture and sell radiation oncology systems in China.

The deal has been signed by Accuray unit Accuray Asia and China Isotope division CNNC High Energy Equipment, which will own 49% and 51% of the JV, respectively.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The new entity will operate as CNNC Accuray Medical Technology in Tianjin, China. It will cater to emerging radiation oncology systems market and longer-term unmet needs in the country.

“The JV is scheduled to start sales operations by the end of the calendar year 2019. Until then, Accuray’s existing Chinese distributor will be responsible for orders and revenue.”

In addition, the JV will leverage both Accuray and CIRC capabilities to offer locally branded and manufactured radiation therapy products.

CNNC Accuray Medical Technology will focus on delivering a complete suite of radiation therapy and radiosurgery treatments for Chinese medical professionals and patients.

Accuray president and CEO Joshua Levine said: “Today’s announcement, which follows an extensive, 18-month evaluation process, advances Accuray’s mission to bring innovative, life-saving radiation products to cancer patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We believe that by uniting CIRC’s strong market access, significant local manufacturing experience and extensive infrastructure in China combined with Accuray’s precise, innovative treatment solutions, the JV will be ideally positioned to effectively address unmet patient needs and improve lives in the world’s largest market for radiation oncology.”

The JV is scheduled to start sales operations by the end of the calendar year 2019. Until then, Accuray’s existing Chinese distributor will be responsible for orders and revenue.

Accuray primarily develops, manufactures and sells radiation oncology systems for the treatment of cancer. The company offers treatment delivery technologies that are designed to enable precision.